Symbols / SMMT $24.58 -6.82% Summit Therapeutics Inc.
SMMT Chart
About
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
Fundamentals
Scroll to Statements| Market Cap | 19.08B | Enterprise Value | 18.37B | Income | -1.08B | Sales | — | Book/sh | 0.85 | Cash/sh | 0.92 |
| Dividend Yield | — | Payout | 0.00% | Employees | 265 | IPO | — | P/E | — | Forward P/E | -20.83 |
| PEG | — | P/S | — | P/B | 28.92 | P/C | — | EV/EBITDA | -16.78 | EV/Sales | — |
| Quick Ratio | 9.78 | Current Ratio | 9.87 | Debt/Eq | 3.17 | LT Debt/Eq | — | EPS (ttm) | -1.44 | EPS next Y | -1.18 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-04-30 | ROA | -115.28% | ROE | -206.10% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 776.08M | Shs Float | 133.88M | Short Float | 23.14% |
| Short Ratio | 13.38 | Short Interest | — | 52W High | 36.91 | 52W Low | 13.83 | Beta | -1.37 | Avg Volume | 2.84M |
| Volume | 8.23M | Target Price | $31.04 | Recom | Buy | Prev Close | $26.38 | Price | $24.58 | Change | -6.82% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-08 | init | Stifel | Buy → Buy | $45 |
| 2026-03-16 | down | Jefferies | Buy → Hold | $15 |
| 2026-02-24 | main | HC Wainwright & Co. | Buy → Buy | $30 |
| 2026-02-02 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2026-01-30 | reit | Citizens | Market Outperform → Market Outperform | $40 |
| 2025-12-17 | up | Barclays | Underweight → Equal-Weight | $18 |
| 2025-11-18 | init | Wolfe Research | — → Peer Perform | — |
| 2025-10-22 | reit | Guggenheim | Buy → Buy | $40 |
| 2025-10-21 | main | Barclays | Underweight → Underweight | $16 |
| 2025-10-21 | main | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-10-20 | main | Citigroup | Buy → Buy | $40 |
| 2025-10-20 | reit | JMP Securities | Market Outperform → Market Outperform | $40 |
| 2025-09-17 | init | Barclays | — → Underweight | $13 |
| 2025-09-16 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-09-08 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2025-09-08 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-09-04 | init | Guggenheim | — → Buy | $40 |
| 2025-09-03 | reit | JMP Securities | Market Outperform → Market Outperform | $40 |
| 2025-09-02 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-08-27 | main | HC Wainwright & Co. | Buy → Buy | $50 |
- Summit Therapeutics (SMMT) jumps as investors refocus on upcoming ivonescimab data and bullish recent coverage - Quiver Quantitative ue, 21 Apr 2026 21
- SMMT Stock Up 24% in Three Months: Here's What You Need to Know - Zacks Investment Research hu, 16 Apr 2026 14
- SMMT Technical Analysis | Trend, Signals & Chart Patterns | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill Mon, 20 Apr 2026 07
- Summit lung cancer drug showed 10.1-month brain PFS in Phase III - Stock Titan Fri, 27 Mar 2026 07
- Positive Outlook for Summit Therapeutics (SMMT) Following ASCO P - GuruFocus ue, 21 Apr 2026 20
- Why Summit Therapeutics Stock Is Sinking Today - TipRanks Wed, 22 Apr 2026 19
- Summit Therapeutics (SMMT) Grabs Investor Attention After Major FDA Breakthrough - Yahoo Finance Mon, 16 Feb 2026 08
- Summit sets Feb. 23 webcast to review Q4 and full-year 2025 results - Stock Titan ue, 17 Feb 2026 22
- $SMMT stock is down 13% today. Here's what we see in our data. - Quiver Quantitative Mon, 12 Jan 2026 08
- Is Summit Therapeutics (SMMT) Still Attractive After Recent Pullback And Multi Year Surge - Yahoo Finance ue, 13 Jan 2026 08
- Board seats, pay and equity plan on ballot at Summit Therapeutics (NASDAQ: SMMT) - Stock Titan Fri, 17 Apr 2026 20
- Is Summit Therapeutics Inc. (SMMT) One of the Most Oversold NASDAQ Stocks to Invest In? - Yahoo Finance hu, 12 Feb 2026 08
- Summit Therapeutics (SMMT) Climbs 15.4% Ahead of Pipeline Q2 Updates - Yahoo Finance Wed, 25 Mar 2026 07
- Summit Therapeutics (SMMT) Valuation Check After Recent Share Price Pullback And Conflicting Model Signals - Yahoo Finance Fri, 30 Jan 2026 08
- A Look At Summit Therapeutics (SMMT) Valuation After Recent Share Price Strength - Yahoo Finance Wed, 07 Jan 2026 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.70
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.70
|
| Operating Expense |
|
1,094.37
+418.72%
|
210.98
+137.76%
|
88.73
+37.95%
|
64.33
|
| Research And Development |
|
537.67
+256.60%
|
150.78
+153.53%
|
59.47
+14.37%
|
52.00
|
| Selling General And Administration |
|
556.70
+824.75%
|
60.20
+105.71%
|
29.26
+9.43%
|
26.74
|
| General And Administrative Expense |
|
556.70
+824.75%
|
60.20
+105.71%
|
29.26
+9.43%
|
26.74
|
| Salaries And Wages |
|
536.70
+979.88%
|
49.70
+151.01%
|
19.80
+3.66%
|
19.10
|
| Other Gand A |
|
20.00
+90.48%
|
10.50
-64.12%
|
29.26
+9.43%
|
26.74
|
| Other Operating Expenses |
|
—
|
—
|
-0.06
+99.44%
|
-9.89
|
| Total Expenses |
|
1,094.37
+418.72%
|
210.98
+137.76%
|
88.73
+37.95%
|
64.33
|
| Operating Income |
|
-1,094.37
-418.72%
|
-210.98
-137.76%
|
-88.73
-39.47%
|
-63.62
|
| Total Operating Income As Reported |
|
—
|
-226.00
+62.93%
|
-609.65
-745.69%
|
-72.09
|
| EBITDA |
|
-1,079.39
-407.89%
|
-212.53
+64.48%
|
-598.27
-718.22%
|
-73.12
|
| Normalized EBITDA |
|
-1,094.28
-418.89%
|
-210.89
-137.52%
|
-88.79
-46.66%
|
-60.54
|
| Reconciled Depreciation |
|
0.15
+64.04%
|
0.09
-55.05%
|
0.20
-84.32%
|
1.26
|
| EBIT |
|
-1,079.54
-407.74%
|
-212.62
+64.47%
|
-598.47
-704.60%
|
-74.38
|
| Total Unusual Items |
|
14.89
+1009.10%
|
-1.64
+99.68%
|
-509.48
-3950.89%
|
-12.58
|
| Total Unusual Items Excluding Goodwill |
|
14.89
+1009.10%
|
-1.64
+99.68%
|
-509.48
-3950.89%
|
-12.58
|
| Special Income Charges |
|
0.00
+100.00%
|
-15.01
+97.12%
|
-520.91
-6051.57%
|
-8.47
|
| Other Special Charges |
|
—
|
15.01
-97.12%
|
520.91
|
—
|
| Impairment Of Capital Assets |
|
—
|
0.00
|
0.00
-100.00%
|
8.47
|
| Net Income |
|
-1,079.59
-387.81%
|
-221.31
+64.01%
|
-614.93
-680.54%
|
-78.78
|
| Pretax Income |
|
-1,079.54
-387.81%
|
-221.30
+64.01%
|
-614.93
-680.54%
|
-78.78
|
| Net Non Operating Interest Income Expense |
|
0.00
+100.00%
|
-8.69
+47.23%
|
-16.46
-469.98%
|
-2.89
|
| Interest Expense Non Operating |
|
0.00
-100.00%
|
8.69
-47.23%
|
16.46
+274.03%
|
4.40
|
| Net Interest Income |
|
0.00
+100.00%
|
-8.69
+47.23%
|
-16.46
-469.98%
|
-2.89
|
| Interest Expense |
|
0.00
-100.00%
|
8.69
-47.23%
|
16.46
+274.03%
|
4.40
|
| Interest Income Non Operating |
|
—
|
13.47
+29.44%
|
10.40
+587.57%
|
1.51
|
| Interest Income |
|
—
|
13.47
+29.44%
|
10.40
+587.57%
|
1.51
|
| Other Income Expense |
|
14.84
+1005.86%
|
-1.64
+99.68%
|
-509.73
-4053.28%
|
-12.27
|
| Other Non Operating Income Expenses |
|
-0.05
|
—
|
-0.25
-182.89%
|
0.30
|
| Gain On Sale Of Security |
|
14.89
+11.38%
|
13.37
+16.91%
|
11.44
+378.29%
|
-4.11
|
| Tax Provision |
|
—
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-1,079.54
-387.81%
|
-221.30
+64.01%
|
-614.93
-680.54%
|
-78.78
|
| Net Income From Continuing Operation Net Minority Interest |
|
-1,079.59
-387.81%
|
-221.31
+64.01%
|
-614.93
-680.54%
|
-78.78
|
| Net Income From Continuing And Discontinued Operation |
|
-1,079.59
-387.81%
|
-221.31
+64.01%
|
-614.93
-680.54%
|
-78.78
|
| Net Income Continuous Operations |
|
-1,079.54
-387.81%
|
-221.30
+64.01%
|
-614.93
-680.54%
|
-78.78
|
| Normalized Income |
|
-1,094.48
-398.22%
|
-219.68
-108.33%
|
-105.45
-59.27%
|
-66.20
|
| Net Income Common Stockholders |
|
-1,079.59
-387.81%
|
-221.31
+64.01%
|
-614.93
-680.54%
|
-78.78
|
| Diluted EPS |
|
-1.44
-364.52%
|
-0.31
+68.69%
|
-0.99
-141.46%
|
-0.41
|
| Basic EPS |
|
-1.44
-364.52%
|
-0.31
+68.69%
|
-0.99
-141.46%
|
-0.41
|
| Basic Average Shares |
|
747.70
+4.06%
|
718.54
+15.96%
|
619.65
+220.50%
|
193.34
|
| Diluted Average Shares |
|
747.70
+4.06%
|
718.54
+15.96%
|
619.65
+220.50%
|
193.34
|
| Diluted NI Availto Com Stockholders |
|
-1,079.59
-387.81%
|
-221.31
+64.01%
|
-614.93
-680.54%
|
-78.78
|
| Other Taxes |
|
—
|
-0.31
+66.91%
|
-0.95
+79.08%
|
-4.52
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
751.18
+72.46%
|
435.56
+114.62%
|
202.95
-69.44%
|
664.17
|
| Current Assets |
|
720.30
+69.98%
|
423.75
+123.36%
|
189.71
-71.11%
|
656.71
|
| Cash Cash Equivalents And Short Term Investments |
|
713.45
+73.02%
|
412.35
+121.40%
|
186.24
-46.58%
|
348.61
|
| Cash And Cash Equivalents |
|
225.27
+114.82%
|
104.86
+46.81%
|
71.42
-79.51%
|
348.61
|
| Cash Equivalents |
|
208.90
+135.78%
|
88.60
+46.79%
|
60.36
-78.93%
|
286.51
|
| Cash Financial |
|
16.37
+0.63%
|
16.26
+46.94%
|
11.07
-82.18%
|
62.09
|
| Other Short Term Investments |
|
488.18
+58.77%
|
307.49
+167.81%
|
114.82
|
0.00
|
| Receivables |
|
—
|
0.56
-34.32%
|
0.85
-86.13%
|
6.12
|
| Accounts Receivable |
|
—
|
—
|
0.00
-100.00%
|
0.35
|
| Other Receivables |
|
—
|
—
|
—
|
1.50
|
| Taxes Receivable |
|
—
|
0.56
-34.32%
|
0.85
-85.29%
|
5.77
|
| Prepaid Assets |
|
—
|
—
|
2.44
+62.30%
|
1.50
|
| Restricted Cash |
|
0.32
-2.77%
|
0.33
|
0.00
-100.00%
|
300.00
|
| Other Current Assets |
|
6.54
-40.98%
|
11.08
+322.43%
|
2.62
+439.51%
|
0.49
|
| Total Non Current Assets |
|
30.88
+161.48%
|
11.81
-10.78%
|
13.24
+77.53%
|
7.46
|
| Net PPE |
|
21.68
+192.98%
|
7.40
+22.02%
|
6.06
+19.33%
|
5.08
|
| Gross PPE |
|
21.68
+192.98%
|
7.40
+4.12%
|
7.11
+11.40%
|
6.38
|
| Accumulated Depreciation |
|
—
|
-1.12
-7.29%
|
-1.04
+19.66%
|
-1.30
|
| Properties |
|
—
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
—
|
1.03
+14.73%
|
0.90
+0.79%
|
0.89
|
| Other Properties |
|
21.68
+192.98%
|
7.40
+25.79%
|
5.88
+25.66%
|
4.68
|
| Leases |
|
—
|
0.32
-1.52%
|
0.33
-59.46%
|
0.81
|
| Goodwill And Other Intangible Assets |
|
2.00
+7.35%
|
1.86
-1.53%
|
1.89
+5.28%
|
1.80
|
| Goodwill |
|
2.00
+7.35%
|
1.86
-1.53%
|
1.89
+5.28%
|
1.80
|
| Other Intangible Assets |
|
—
|
—
|
—
|
—
|
| Non Current Accounts Receivable |
|
—
|
0.70
-27.22%
|
0.96
|
—
|
| Other Non Current Assets |
|
7.21
+182.77%
|
2.55
-41.05%
|
4.32
+649.05%
|
0.58
|
| Total Liabilities Net Minority Interest |
|
92.32
+97.22%
|
46.81
-62.63%
|
125.26
-76.70%
|
537.51
|
| Current Liabilities |
|
72.99
+74.91%
|
41.73
+104.50%
|
20.41
-47.39%
|
38.78
|
| Payables And Accrued Expenses |
|
52.39
+116.59%
|
24.19
+111.27%
|
11.45
+3.91%
|
11.02
|
| Payables |
|
20.29
+337.70%
|
4.64
+73.83%
|
2.67
+651.27%
|
0.35
|
| Accounts Payable |
|
20.29
+337.70%
|
4.64
+73.83%
|
2.67
+651.27%
|
0.35
|
| Current Accrued Expenses |
|
32.10
+64.16%
|
19.55
+122.63%
|
8.78
-17.64%
|
10.66
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
14.93
+24.61%
|
11.98
+120.61%
|
5.43
-3.76%
|
5.64
|
| Current Debt And Capital Lease Obligation |
|
3.39
-10.01%
|
3.77
+34.03%
|
2.81
-86.91%
|
21.46
|
| Current Debt |
|
—
|
—
|
—
|
19.77
|
| Current Capital Lease Obligation |
|
3.39
-10.01%
|
3.77
+34.03%
|
2.81
+66.21%
|
1.69
|
| Current Deferred Liabilities |
|
—
|
—
|
—
|
0.00
|
| Current Deferred Revenue |
|
—
|
—
|
—
|
0.00
|
| Other Current Liabilities |
|
2.28
+27.05%
|
1.80
+150.63%
|
0.72
+8.31%
|
0.66
|
| Total Non Current Liabilities Net Minority Interest |
|
19.33
+280.37%
|
5.08
-95.15%
|
104.85
-78.98%
|
498.73
|
| Long Term Debt And Capital Lease Obligation |
|
17.50
+406.86%
|
3.45
-96.66%
|
103.29
-79.23%
|
497.30
|
| Long Term Debt |
|
—
|
—
|
100.00
-79.78%
|
494.54
|
| Long Term Capital Lease Obligation |
|
17.50
+406.86%
|
3.45
+4.95%
|
3.29
+19.07%
|
2.76
|
| Non Current Deferred Liabilities |
|
—
|
—
|
—
|
—
|
| Non Current Deferred Revenue |
|
—
|
—
|
—
|
—
|
| Other Non Current Liabilities |
|
1.83
+12.39%
|
1.63
+4.35%
|
1.56
+9.31%
|
1.43
|
| Stockholders Equity |
|
658.86
+69.48%
|
388.75
+400.37%
|
77.69
-38.66%
|
126.65
|
| Common Stock Equity |
|
658.86
+69.48%
|
388.75
+400.37%
|
77.69
-38.66%
|
126.65
|
| Capital Stock |
|
7.75
+5.12%
|
7.38
+5.12%
|
7.02
+232.56%
|
2.11
|
| Common Stock |
|
7.75
+5.12%
|
7.38
+5.12%
|
7.02
+232.56%
|
2.11
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
775.37
+5.12%
|
737.63
+5.13%
|
701.66
+232.40%
|
211.09
|
| Ordinary Shares Number |
|
775.37
+5.12%
|
737.63
+5.13%
|
701.66
+232.40%
|
211.09
|
| Additional Paid In Capital |
|
2,947.80
+84.44%
|
1,598.23
+49.87%
|
1,066.38
+111.26%
|
504.77
|
| Retained Earnings |
|
-2,294.16
-88.89%
|
-1,214.57
-22.28%
|
-993.26
-162.54%
|
-378.33
|
| Gains Losses Not Affecting Retained Earnings |
|
-2.54
-11.16%
|
-2.29
+6.66%
|
-2.45
-29.32%
|
-1.89
|
| Other Equity Adjustments |
|
-2.54
-11.16%
|
-2.29
+6.66%
|
-2.45
-29.32%
|
-1.89
|
| Total Equity Gross Minority Interest |
|
658.86
+69.48%
|
388.75
+400.37%
|
77.69
-38.66%
|
126.65
|
| Total Capitalization |
|
658.86
+69.48%
|
388.75
+118.78%
|
177.69
-71.40%
|
621.19
|
| Working Capital |
|
647.31
+69.44%
|
382.02
+125.64%
|
169.31
-72.60%
|
617.93
|
| Invested Capital |
|
658.86
+69.48%
|
388.75
+118.78%
|
177.69
-72.28%
|
640.96
|
| Total Debt |
|
20.89
+189.42%
|
7.22
-93.20%
|
106.10
-79.55%
|
518.76
|
| Net Debt |
|
—
|
—
|
28.57
-82.76%
|
165.70
|
| Capital Lease Obligations |
|
20.89
+189.42%
|
7.22
+18.35%
|
6.10
+36.96%
|
4.45
|
| Net Tangible Assets |
|
656.86
+69.78%
|
386.88
+410.41%
|
75.80
-39.29%
|
124.86
|
| Tangible Book Value |
|
656.86
+69.78%
|
386.88
+410.41%
|
75.80
-39.29%
|
124.86
|
| Current Notes Payable |
|
—
|
—
|
0.00
-100.00%
|
19.77
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-322.93
-127.25%
|
-142.11
-85.13%
|
-76.76
-84.60%
|
-41.58
|
| Cash Flow From Continuing Operating Activities |
|
-322.93
-127.25%
|
-142.11
-85.13%
|
-76.76
-84.60%
|
-41.58
|
| Net Income From Continuing Operations |
|
-1,079.59
-387.81%
|
-221.31
+64.01%
|
-614.93
-680.54%
|
-78.78
|
| Depreciation Amortization Depletion |
|
0.15
+64.04%
|
0.09
-55.05%
|
0.20
-84.32%
|
1.26
|
| Depreciation |
|
0.15
+64.04%
|
0.09
-55.05%
|
0.20
-43.27%
|
0.35
|
| Amortization Cash Flow |
|
—
|
0.00
|
0.00
-100.00%
|
0.91
|
| Depreciation And Amortization |
|
0.15
+64.04%
|
0.09
-55.05%
|
0.20
-84.32%
|
1.26
|
| Amortization Of Intangibles |
|
—
|
0.00
|
0.00
-100.00%
|
0.91
|
| Other Non Cash Items |
|
—
|
15.01
-97.15%
|
527.17
+17252.47%
|
3.04
|
| Stock Based Compensation |
|
732.42
+1336.65%
|
50.98
+261.36%
|
14.11
+18.08%
|
11.95
|
| Asset Impairment Charge |
|
0.00
|
0.00
-100.00%
|
0.47
-94.40%
|
8.47
|
| Operating Gains Losses |
|
-0.32
-239.74%
|
0.23
+117.09%
|
-1.34
-151.22%
|
2.62
|
| Net Foreign Currency Exchange Gain Loss |
|
-0.32
-239.74%
|
0.23
+118.60%
|
-1.23
-147.06%
|
2.62
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
-0.11
|
0.00
|
| Change In Working Capital |
|
31.42
+102.96%
|
15.48
+3099.81%
|
-0.52
-105.23%
|
9.87
|
| Change In Receivables |
|
—
|
0.54
-88.18%
|
4.53
-51.90%
|
9.41
|
| Changes In Account Receivables |
|
—
|
0.00
-100.00%
|
0.36
-63.18%
|
0.97
|
| Change In Prepaid Assets |
|
4.87
+166.02%
|
-7.37
-303.99%
|
3.61
-29.25%
|
5.11
|
| Change In Payables And Accrued Expense |
|
31.14
+52.28%
|
20.45
+5959.89%
|
-0.35
-115.45%
|
2.26
|
| Change In Accrued Expense |
|
15.84
-14.09%
|
18.44
+805.82%
|
-2.61
-140.87%
|
6.39
|
| Change In Payable |
|
15.30
+659.45%
|
2.02
-10.96%
|
2.26
+154.77%
|
-4.13
|
| Change In Account Payable |
|
15.30
+659.45%
|
2.02
-10.96%
|
2.26
+154.77%
|
-4.13
|
| Change In Other Working Capital |
|
0.20
+221.56%
|
-0.17
+53.48%
|
-0.36
+94.96%
|
-7.13
|
| Change In Other Current Assets |
|
-4.88
-297.37%
|
2.47
+172.20%
|
-3.42
-1691.16%
|
0.21
|
| Change In Other Current Liabilities |
|
0.08
-15.79%
|
0.10
|
0.00
|
0.00
|
| Investing Cash Flow |
|
-174.31
+15.11%
|
-205.34
+65.06%
|
-587.77
-94094.55%
|
-0.62
|
| Cash Flow From Continuing Investing Activities |
|
-174.31
+15.11%
|
-205.34
+65.06%
|
-587.77
-94094.55%
|
-0.62
|
| Net PPE Purchase And Sale |
|
-0.66
-372.66%
|
-0.14
-241.84%
|
0.10
+115.71%
|
-0.62
|
| Purchase Of PPE |
|
-0.66
-372.66%
|
-0.14
-8.59%
|
-0.13
+79.49%
|
-0.62
|
| Sale Of PPE |
|
0.00
|
0.00
-100.00%
|
0.23
|
0.00
|
| Capital Expenditure |
|
-0.66
-372.66%
|
-0.14
-8.59%
|
-0.13
+79.49%
|
-0.62
|
| Net Investment Purchase And Sale |
|
-173.65
+8.70%
|
-190.19
-68.53%
|
-112.86
|
0.00
|
| Purchase Of Investment |
|
-484.99
+28.68%
|
-680.03
-111.83%
|
-321.02
|
0.00
|
| Sale Of Investment |
|
311.34
-36.44%
|
489.84
+135.31%
|
208.16
|
0.00
|
| Net Other Investing Changes |
|
—
|
-15.01
+96.84%
|
-475.01
|
—
|
| Financing Cash Flow |
|
617.53
+61.99%
|
381.23
+340.66%
|
86.51
-86.05%
|
620.24
|
| Cash Flow From Continuing Financing Activities |
|
617.53
+61.99%
|
381.23
+340.66%
|
86.51
-86.05%
|
620.24
|
| Net Issuance Payments Of Debt |
|
0.00
+100.00%
|
-100.00
-305.09%
|
-24.69
-104.75%
|
520.00
|
| Issuance Of Debt |
|
—
|
0.00
|
0.00
-100.00%
|
545.00
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-100.00
-305.09%
|
-24.69
+1.26%
|
-25.00
|
| Long Term Debt Issuance |
|
—
|
0.00
|
0.00
-100.00%
|
545.00
|
| Long Term Debt Payments |
|
0.00
+100.00%
|
-100.00
-305.09%
|
-24.69
+1.26%
|
-25.00
|
| Net Long Term Debt Issuance |
|
0.00
+100.00%
|
-100.00
-305.09%
|
-24.69
-104.75%
|
520.00
|
| Net Common Stock Issuance |
|
604.57
+26.51%
|
477.89
+335.69%
|
109.69
+9.69%
|
100.00
|
| Proceeds From Stock Option Exercised |
|
12.97
+288.96%
|
3.33
+56.38%
|
2.13
+434.34%
|
0.40
|
| Net Other Financing Charges |
|
—
|
—
|
-0.62
-299.35%
|
-0.15
|
| Changes In Cash |
|
120.29
+256.11%
|
33.78
+105.84%
|
-578.02
-200.00%
|
578.04
|
| Effect Of Exchange Rate Changes |
|
0.10
+666.67%
|
-0.02
-102.15%
|
0.84
+168.66%
|
-1.22
|
| Beginning Cash Position |
|
105.19
+47.27%
|
71.42
-88.99%
|
648.61
+803.47%
|
71.79
|
| End Cash Position |
|
225.58
+114.46%
|
105.19
+47.27%
|
71.42
-88.99%
|
648.61
|
| Free Cash Flow |
|
-323.59
-127.49%
|
-142.25
-85.00%
|
-76.89
-82.17%
|
-42.21
|
| Interest Paid Supplemental Data |
|
0.00
-100.00%
|
8.81
-17.31%
|
10.65
+2353.92%
|
0.43
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
-100.00%
|
0.05
|
0.00
|
| Amortization Of Securities |
|
-7.01
-171.97%
|
-2.58
-33.89%
|
-1.92
|
0.00
|
| Common Stock Issuance |
|
604.57
+26.51%
|
477.89
+335.69%
|
109.69
+9.69%
|
100.00
|
| Issuance Of Capital Stock |
|
604.57
+26.51%
|
477.89
+335.69%
|
109.69
+9.69%
|
100.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-02-23 View
- 8-K2026-02-23 View
- 8-K2026-01-29 View
- 42026-01-12 View
- 8-K2026-01-12 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 8-K2025-11-07 View
- 42025-10-23 View
- 42025-10-23 View
- 42025-10-23 View
- 42025-10-23 View
- 42025-10-23 View
- 8-K2025-10-22 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|